ideasIdea
Treat the draining lymph node before removing it
The first lymph node cancer reaches is also where the immune system learns to fight it. Injecting immunotherapy into that node before surgery, instead of removing it blindly, may work better.
Tumour-draining lymph nodes hold the stem-like precursor T cells that checkpoint blockade depends on, so removing or irradiating them may remove the substrate of response. Peritumoural or intranodal injection achieves high nodal exposure at a small fraction of the systemic dose, and small trials of peritumoural nivolumab in oral cancer and intratumoural ipilimumab in melanoma showed nodal immune activation.
Hypothesis
Low-dose peritumoural or intranodal checkpoint blockade before surgery produces pathological response at least as good as systemic dosing, with fewer immune-related adverse events, in early oral cavity cancer and melanoma.
Rationale
Antigen presentation and T-cell priming happen in the node, not the tumour, while the dose-limiting toxicity of checkpoint blockade is systemic. Concentrating the drug where priming occurs is a pharmacology argument rather than a new mechanism.
What would test it
Randomised neoadjuvant window trial comparing low-dose peritumoural against standard intravenous checkpoint blockade, with major pathological response and nodal immune profiling as co-primary endpoints.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
6
Bottlenecks it attacks
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Cold tumours and the immunosuppressive microenvironment · Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.